Author pages are created from data sourced from our academic publisher partnerships and public sources.
Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3.
- A. Mangia, R. Santoro, +12 authors A. Andriulli
- The New England journal of medicine
- 23 June 2005
BACKGROUND We hypothesized that in patients with hepatitis C virus (HCV) genotype 2 or 3 in whom HCV RNA is not detectable after 4 weeks of therapy, 12 weeks of treatment is as effective as 24 weeks.… Expand
Individualized treatment duration for hepatitis C genotype 1 patients: A randomized controlled trial
It was hypothesized that in hepatitis C virus (HCV) genotype 1 patients, variable treatment duration individualized by first undetectable HCV RNA is as effective as standard 48‐week treatment.… Expand
Determinants of relapse after a short (12 weeks) course of antiviral therapy and re‐treatment efficacy of a prolonged course in patients with chronic hepatitis C virus genotype 2 or 3 infection
In hepatitis C virus (HCV) genotypes 2 and 3 patients, the high rate of relapse after 12 to 16 weeks of antiviral therapy is the main concern for shortening treatment duration. This study was… Expand
Risk factors and outcome among a large patient cohort with community-acquired acute hepatitis C in Italy.
- T. Santantonio, E. Medda, +12 authors T. Stroffolini
- Clinical infectious diseases : an official…
- 1 November 2006
BACKGROUND The epidemiology of acute hepatitis C has changed during the past decade in Western countries. Acute HCV infection has a high rate of chronicity, but it is unclear when patients with acute… Expand
Epidemiological and clinical features of HEV infection: a survey in the district of Foggia (Apulia, Southern Italy).
In this study we assessed the seroprevalence of hepatitis E virus (HEV) infection in both the Italian population and immigrants from developing countries in Foggia (Apulia, Southern Italy). The… Expand
Peg-interferon alpha-2a versus Peg-interferon alpha-2b in nonresponders with HCV active chronic hepatitis: a pilot study.
- G. Scotto, V. Fazio, +4 authors G. Angarano
- Journal of interferon & cytokine research : the…
- 24 September 2008
BACKGROUND The efficacy and tolerability of Peg-Interferon alpha-2a (Peg-IFNalpha-2a) versus Peg-Interferon alpha-2b (Peg-IFNalpha-2b) were compared in a patient cohort with hepatitis C virus… Expand
QuantiFERON-TB Gold In-Tube test (QFT-GIT) for the screening of latent tuberculosis in recent immigrants to Italy.
To evaluate the agreement between QuantiFERON-TB Gold In-Tube test (QFT-GIT) and tuberculin skin test (TST) for the screening of latent tuberculosis infection (LTBI) in recent immigrants to Italy,… Expand
Seroprevalence of hepatitis E virus among blood donors in a district of southern Italy.
- G. Scotto, A. Giammario, M. Centra, F. Vittorio, D. Martinelli, V. Fazio
- Blood transfusion = Trasfusione del sangue
- 31 May 2012
Dear Sir, Hepatitis E virus (HEV) is a single-stranded RNA virus that is the major aetiological agent of enteric non-A hepatitis. Once thought to be confined to developing countries, where it is… Expand
Interferon alpha-2B and ribavirin in combination for patients with chronic hepatitis C who failed to respond to, or relapsed after, interferon alpha therapy: a randomized trial.
- G. Barbaro, G. Di Lorenzo, +17 authors G. Barbarini
- The American journal of medicine
- 1 August 1999
PURPOSE To assess the efficacy of interferon alpha-2b and ribavirin in combination in the treatment of patients with chronic hepatitis C who had either failed to respond to therapy with interferon… Expand
Recommendations for the prevention, diagnosis, and treatment of chronic hepatitis B and C in special population groups (migrants, intravenous drug users and prison inmates).
- P. Almasio, S. Babudieri, +14 authors G. Starnini
- Digestive and liver disease : official journal of…
- 1 August 2011
The global spread of hepatitis B virus (HBV) and hepatitis C virus (HCV), their high chronicity rates and their progression to cirrhosis and hepatocellular carcinoma, are major public health… Expand